Medtronic, Inc. (NYSE: MDT) announced the global launch and first clinical use of the Tri-Ad™ Semi-Flexible Tricuspid Annuloplasty Ring for the treatment of tricuspid valve disease. The ring is designed to adapt to the movement of a diseased patient's natural valve to help restore the valve to its normal size and shape. The Tri-Ad ring recently received clearance for use in the U.S. and Europe, expanding Medtronic's surgical heart valve repair product portfolio...
More...
More...